Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep-Oct;16(5):710-4.
doi: 10.4103/1008-682X.129131.

Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy

Affiliations

Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy

Jian-Ping Wu et al. Asian J Androl. 2014 Sep-Oct.

Abstract

Reactive stromal changes in prostate cancer (PCa) are likely involved in the emergence of castration-resistant PCa (CRPC). This study was designed to investigate stromal changes in patients with clinically advanced PCa and analyze their prognostic significance. Prostate needle biopsies obtained from 148 patients before castration therapy were analyzed by Masson trichrome staining and immunohistochemical analysis of vimentin and desmin. Reactive stroma grading was inversely correlated with Gleason score. Stroma grade (Masson stain 82.8% vs 45.6%, P < 0.001) and vimentin expression (P = 0.005) were significantly higher, and desmin expression (P = 0.004) significantly lower, in reactive stroma of tumors with a Gleason score of 6-7 than in adjacent peritumoral tissue. Kaplan-Meier analysis showed a significant association between reactive stroma grade in tumors and the occurrence of CRPC in patients with a Gleason score of 6-7 (P = 0.009). Furthermore, patients with higher vimentin or lower desmin expression had a shorter disease-free period. In multivariate analysis, only vimentin expression was a significant predictor of tumor relapse (hazard ratio 1.78, 95% confidence interval 1.12-10.26, P = 0.012). These findings indicate that the intensity of reactive stroma is associated with castration responsiveness, especially in patients with a lower Gleason score where the abundant stroma component is most frequently found. High expression of vimentin in tumor stroma was independently associated with poor outcomes in patients with Gleason scores of 6-7, and may serve as a new prognostic marker in daily practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Stromal cell phenotype in prostate cancer detected by (a) Masson trichrome staining (×200), (b) vimentin (×100), and (c) desmin (×100). Scale bars = 20 μm.
Figure 2
Figure 2
Distribution of reactive stroma in tumors with different Gleason score. (a) Stroma grade in the tumors with Gleason score of 6–7, (b) Stroma grade in peritumoral tissue with Gleason score of 6–7, (c) Stroma grade in the tumors with Gleason score of 8-9, (d) Stroma grade in peritumoral tissue with Gleason score of 8–9.
Figure 3
Figure 3
Kaplan-Meier analysis showed a significant association between intensity of reactive stroma and the occurrence of castration-resistant prostate cancer in tumors with Gleason score of 6–7 (log-rank P = 0.009, (a). Patients with higher vimentin expression (log-rank P = 0.044, (b) or lower desmin expression (log-rank P = 0.045, (c) had a shorter disease-free period.

References

    1. Donkena KV, Yuan H, Young CY. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets. 2010;10:402–10. - PubMed
    1. Thalmann GN, Rhee H, Sikes RA, Pathak S, Multani A, et al. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. Eur Urol. 2010;58:162–71. - PMC - PubMed
    1. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA. 2008;105:12188–93. - PMC - PubMed
    1. Burnstein KL. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem. 2005;95:657–69. - PubMed
    1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253–61. - PubMed

Publication types

MeSH terms